Pre-Existing and Acquired Resistance to PARP Inhibitor-Induced Synthetic Lethality

SIMPLE SUMMARY: PARP inhibitors (PARPi) have been administered to treat BRCA1/2-mutated/deficient malignancies. Nevertheless, the resistance to PARPi is emerging in experimental and clinical interventions. Importantly, the resistance originated from diverse mechanisms, therefore requiring tremendous...

Descripción completa

Detalles Bibliográficos
Autores principales: Le, Bac Viet, Podszywałow-Bartnicka, Paulina, Piwocka, Katarzyna, Skorski, Tomasz
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9741207/
https://www.ncbi.nlm.nih.gov/pubmed/36497275
http://dx.doi.org/10.3390/cancers14235795

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9741207/
https://www.ncbi.nlm.nih.gov/pubmed/36497275
http://dx.doi.org/10.3390/cancers14235795

Ejemplares similares